use of ecarin clotting time (ect) with  xxxd2455xxx  therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.  heparin-induced thrombocytopenia (hit) is described as an allergy-like adverse reaction to heparin. it is a potentially severe complication of heparin therapy that can result in serious or life-threatening venous or arterial thromboembolic events. in the united states,  xxxd2455xxx  (aventis pharma ag, strasbourg, france) is an approved therapy for anticoagulation in patients with hit requiring anticoagulation.  xxxd2455xxx  is a recombinant form of hirudin, a leech enzyme that is a highly specific direct inhibitor of thrombin.  xxxd2455xxx  monitoring during surgery can be managed with ecarin clotting time (ect) (cardiovascular diagnostics, inc., raleigh, nc), which has recently been approved as a humanitarian device exemption (hde) for use in the united states in the management of hit with cardiopulmonary bypass. this case report describes a patient with hit who was managed successfully with  xxxd2455xxx  and ect during coronary artery bypass grafting.